Hayward, United States
RefleXion Medical is a pioneering company that has gained $105.00M in Venture Round investment on 15 November 2023. The company, founded in 2009 and headquartered in the United States, operates in the Biotechnology and Health Care industries. RefleXion Medical's breakthrough technology, SCINTIX® therapy, has recently received FDA clearance and represents a significant advancement in the field of biology-guided radiotherapy. This innovative therapy detects and responds to signals emitted from cancer, using them to deliver immediate treatment for tumors in the lung or bone arising from primary or metastatic disease.
The recent Venture Round investment was led by a consortium of prominent investors, including Johnson & Johnson Innovation, Venrock, The Rise Fund, T. Rowe Price, Ally Bridge Group, Banque Pictet, Catalio Capital Management, Squarepoint Capital, Pfizer Venture Investments, and Hillenbrand Capital Partners, LLC.
This substantial investment underscores the confidence of industry leaders in RefleXion Medical's pioneering approach and the potential impact of SCINTIX® therapy on the treatment of cancer. The company's FDA clearance further solidifies its position as a frontrunner in the development of innovative and effective cancer treatment solutions.
